Gilead Sciences, Inc.GILDNASDAQ
$0.00+0.00 (+0.00%)
CLOSED
Prev —|Open —|Day —–—|Vol —
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +7.02% | +6.40% | -0.28% | +1.84% | +2.97% |
| Gross Profit Growth | +8.86% | +19.19% | -0.14% | +3.16% | +3.84% |
| EBITDA Growth | -41.74% | +19.90% | +0.00% | +13.07% | +143.26% |
| Operating Income Growth | -66.15% | +52.11% | +0.00% | -6.43% | +274.66% |
| Net Income Growth | -42.52% | +24.77% | +0.00% | +21.44% | +143.58% |
| EPS Growth | -42.86% | +24.35% | +0.00% | +21.71% | +146.00% |
| EPS Diluted Growth | -42.20% | +24.56% | +0.00% | +20.93% | +143.00% |
| Weighted Average Shares Growth | -0.08% | +0.00% | -0.08% | -0.16% | -0.32% |
| Weighted Average Shares Diluted Growth | -0.24% | +0.24% | +0.96% | +0.32% | +0.00% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +145.53% | +37.16% | -20.82% | -37.58% | -4.66% |
| Free Cash Flow Growth | +155.24% | +44.73% | -21.81% | -39.75% | -4.97% |
| Receivables Growth | -4.24% | -5.15% | -6.02% | +2.53% | +11.07% |
| Inventory Growth | +12.39% | -4.31% | -5.07% | -9.92% | -4.49% |
| Asset Growth | -12.58% | -5.04% | +0.25% | +4.00% | +7.35% |
| Book Value per Share Growth | -17.14% | -15.34% | +9.34% | +7.80% | +16.97% |
| Debt Growth | -6.94% | +6.49% | -0.96% | +6.84% | +7.28% |
| R&D Expense Growth | -4.26% | +16.55% | -9.28% | +10.36% | -3.51% |
| SG&A Expenses Growth | +7.22% | +17.78% | -8.51% | -0.87% | -3.76% |